Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
-$0.33 today
- Market cap
- $1.37B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
Volume 0.04M
Average 0.08M
NBTX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Nanobiotix S.A.NASDAQ: NBTX
Revenue · Q4 FY2025 · quarter ended Dec 2025
Revenue turns positive
Q4 FY2025 revenue was €3.01M, compared with -€16.48M a year earlier. Over 3 fiscal years it compounded at +83.8% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of €25.46M (-14.1%) for the fiscal year ending Dec 2026, a slowdown from the +512.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- €3.01M— QoQ
- Last fiscal yearDec 2025
- €29.64M+512.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +118.2% | — | — |
| 1 year | +512.3% | -14.1% | -526.4 pp |
| 3-year CAGR | +83.8% | +47.2% | -36.6 pp |
| 5-year CAGR | +37.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
EUR · from the income statement
- Latest · FY2025
- 29.64M EUR
- Year-over-year change
- +512.3%
- 4-year CAGR
- +82.9%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.64M | +512.3% |
| FY2024 | 2024-12-31 | (7.19M) | -119.9% |
| FY2023 | 2023-12-31 | 36.21M | +658.1% |
| FY2022 | 2022-12-31 | 4.78M | +80.4% |
| FY2021 | 2021-12-31 | 2.65M | — |
Revenue vs competitors
How NBTX compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +512.3% is the highest of 6, against a peer median of +5.4%.
- Over three fiscal years its annual growth of +83.8% compares with a peer median of +339.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $227.18M USD | -2.4% | +0.0% | |
| LTM Mar 2026 | $217.17M USD | +396.7% | — | |
| LTM Sep 2026 | $182.57M USD | +121.2% | +678.6% | |
| LTM Mar 2026 | $71.64M USD | +5.4% | — | |
| FY2025 | €29.64M EUR | +512.3% | +83.8% | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | -100.0% | — | |
| Peer median (excluding NBTX) | — | +5.4% | +339.3% | |
Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.65M | 4.78M | 36.21M | (7.19M) | 29.64M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 2.65M | 4.78M | 36.21M | (7.19M) | 29.64M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 30.38M | 32.64M | 38.4M | 40.54M | 23.12M |
| Selling, General & Admin | 19.43M | 17.86M | 22.05M | 20.53M | 20.22M |
| Operating Expenses | 55.23M | 51.48M | 62.99M | 61.2M | 40.46M |
| Depreciation & Amortization | 1.56M | 1.5M | 551K | 592K | 1.5M |
| EBITDA | (45.61M) | (44.22M) | (23.69M) | (67.67M) | (12.07M) |
| EBITDA Margin | -1722.9% | -925.8% | -65.4% | 941.1% | -40.7% |
| Operating Income | (52.58M) | (46.7M) | (26.78M) | (68.39M) | (10.82M) |
| Operating Margin | -1986.4% | -977.8% | -74.0% | 951.2% | -36.5% |
| Interest Income | 0 | 256K | 1.22M | 2.63M | 985K |
| Interest Expense | 699.49K | 5.84M | 7.98M | 8.09M | 10.4M |
| Other Income / Expenses | 5.58M | (10.33M) | (12.8M) | 361K | (13.14M) |
| Income Before Tax | (47M) | (57.03M) | (39.58M) | (68.03M) | (23.96M) |
| Pre-Tax Margin | -1775.5% | -1194.1% | -109.3% | 946.2% | -80.8% |
| Income Tax Expense | 5K | 10K | 120K | 101K | 3K |
| Net Income | (47M) | (57.04M) | (39.7M) | (68.13M) | (23.96M) |
| Net Margin | -1775.7% | -1194.3% | -109.6% | 947.6% | -80.8% |
| EPS (Basic) | (1.35) | (1.64) | (1.08) | (1.44) | (0.50) |
| EPS (Diluted) | (1.35) | (1.64) | (1.08) | (1.44) | (0.50) |
| Weighted Avg Shares | 34.73M | 34.85M | 36.76M | 47.27M | 47.82M |
| Weighted Avg Shares (Diluted) | 34.73M | 34.85M | 36.93M | 47.27M | 47.82M |
Nanobiotix S.A.
NASDAQ:NBTX
Intrinsic Alpha fair value
Locked
Current Price
$26.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.